Shots:
- Integer and KKR have entered into a definitive agreement under which an affiliate of investment funds managed by KKR will acquire Integer, delisting it from NYSE
- As per the deal, KKR will acquire Integer in an all-cash transaction valued at $127 per share, representing the total enterprise value of ~$5.7B
- As a KKR portfolio company, Integer will gain long-term capital and greater flexibility to invest in capacity, technology, innovation, and talent to better support customers and patients
Ref: Integer | Image: Integer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
